Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy

DMM Disease Models and Mechanisms

Volumn 7, Issue 11, 2014, Pages 1253-1261

  Barthélémy, Inès ^a   Pinto Mariz, Fernanda ^b,c,d   Yada, Erica ^b   Desquilbet, Loïc ^a,e   Savino, Wilson ^d   Silva Barbosa, Suse Dayse ^f   Faussat, Anne Marie ^b   Mouly, Vincent ^b   Voit, Thomas ^b   Blot, Stéphane ^a   Butler Browne, Gillian ^b  

^a UNIVERSITÉ PARIS EST   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e MNHN   (France)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Accelerometry; CD49d; DMD; Dog; Dystrophin; Gait analysis; GRMD; Lymphocyte; Predictive biomarker

Indexed keywords

ALPHA4 INTEGRIN; BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN;

ACCELEROMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE MODEL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; GAIT; GOLDEN RETRIEVER; MOBILIZATION; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; ANIMAL; BLOOD; DISEASE MODEL; DOG; IMMUNOLOGY; IMMUNOPHENOTYPING; PATHOPHYSIOLOGY;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOGS; IMMUNOPHENOTYPING; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84919979720     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.016014     Document Type: Article

References (24)

1. Ambrósio, C. E., Fadel, L., Gaiad, T. P., Martins, D. S., Araújo, K. P., Zucconi, E., Brolio, M. P., Giglio, R. F., Morini, A. C., Jazedje, T. et al. (2009). Identification of three distinguishable phenotypes in golden retriever muscular dystrophy. Genet. Mol. Res. 8, 389-396.
2. Banks, G. B. and Chamberlain, J. S. (2008). The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol. 84, 431-453.
3. Barthélémy, I., Barrey, E., Thibaud, J. L., Uriarte, A., Voit, T., Blot, S. and Hogrel, J. Y. (2009). Gait analysis using accelerometry in dystrophin-deficient dogs. Neuromuscul. Disord. 19, 788-796.
4. Barthélémy, I., Barrey, E., Aguilar, P., Uriarte, A., Le Chevoir, M., Thibaud, J. L., Voit, T., Blot, S. and Hogrel, J. Y. (2011). Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskelet. Disord. 12, 75.
5. Barthélémy, I., Uriarte, A., Drougard, C., Unterfinger, Y., Thibaud, J. L. and Blot, S. (2012). Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy. PLoS ONE 7, e48478.
6. Bartlett, R. J., Winand, N. J., Secore, S. L., Singer, J. T., Fletcher, S., Wilton, S., Bogan, D. J., Metcalf-Bogan, J. R., Bartlett, W. T., Howell, J. M. et al. (1996). Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am. J. Vet. Res. 57, 650-654.
7. Bartolomé, R. A., Sanz-Rodríguez, F., Robledo, M. M., Hidalgo, A. and Teixidó, J. (2003). Rapid up-regulation of alpha4 integrin-mediated leukocyte adhesion by transforming growth factor-beta1. Mol. Biol. Cell 14, 54-66.
8. Bello, L., Piva, L., Barp, A., Taglia, A., Picillo, E., Vasco, G., Pane, M., Previtali, S. C., Torrente, Y., Gazzerro, E. et al. (2012). Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 79, 159-162.
9. Deconinck, N. and Dan, B. (2007). Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36, 1-7.
10. Desguerre, I., Christov, C., Mayer, M., Zeller, R., Becane, H. M., Bastuji-Garin, S., Leturcq, F., Chiron, C., Chelly, J. and Gherardi, R. K. (2009a). Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE 4, e4347.
11. Desguerre, I., Mayer, M., Leturcq, F., Barbet, J. P., Gherardi, R. K. and Christov, C. (2009b). Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J. Neuropathol. Exp. Neurol. 68, 762-773.
12. Desquilbet, L. and Mariotti, F. (2010). Dose-response analyses using restricted cubic spline functions in public health research. Stat. Med. 29, 1037-1057.
13. Duan, D. (2011). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2011, 31-42.
14. Flanigan, K. M., Ceco, E., Lamar, K. M., Kaminoh, Y., Dunn, D. M., Mendell, J. R., King, W. M., Pestronk, A., Florence, J. M., Mathews, K. D. et al.; United Dystrophinopathy Project (2013). LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann. Neurol. 73, 481-488.
15. Humbertclaude, V., Hamroun, D., Bezzou, K., Bérard, C., Boespflug-Tanguy, O., Bommelaer, C., Campana-Salort, E., Cances, C., Chabrol, B., Commare, M. C. et al. (2012). Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur. J. Paediatr. Neurol. 16, 149-160.
16. Marsh, A. P., Eggebeen, J. D., Kornegay, J. N., Markert, C. D. and Childers, M. K. (2010). Kinematics of gait in golden retriever muscular dystrophy. Neuromuscul. Disord. 20, 16-20.
17. McDonald, C. M., Abresch, R. T., Carter, G. T., Fowler, W. M., Jr, Johnson, E. R., Kilmer, D. D. and Sigford, B. J. (1995). Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am. J. Phys. Med. Rehabil. 74 Suppl. 1, S70-S92.
18. Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., Ermani, M., Bello, L., Soraru, G., Pacchioni, B., Bonifati, M. D. et al.; Cooperative International Neuromuscular Research Group (2011). SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76, 219-226.
19. Pinto-Mariz, F., Carvalho, L. R., de Mello, W., Araújo, A. Q., Ribeiro, M. G., Cunha, M. C., Voit, T., Butler-Browne, G., Silva-Barbosa, S. D. and Savino, W. (2010). Differential integrin expression by T lymphocytes: potential role in DMD muscle damage. J. Neuroimmunol. 223, 128-130.
20. Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F.; NorthStar Clinical Network (2013). Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psychiatry 84, 698-705.
21. Thibaud, J. L., Monnet, A., Bertoldi, D., Barthélémy, I., Blot, S. and Carlier, P. G. (2007). Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul. Disord. 17, 575-584.
22. Thibaud, J. L., Azzabou, N., Barthelemy, I., Fleury, S., Cabrol, L., Blot, S. and Carlier, P. G. (2012). Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul. Disord. 22 Suppl. 2, S85-S99.
23. Valentine, B. A., Cooper, B. J., de Lahunta, A., O'Quinn, R. and Blue, J. T. (1988). Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci. 88, 69-81.
24. Willmann, R., Possekel, S., Dubach-Powell, J., Meier, T. and Ruegg, M. A. (2009). Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul. Disord. 19, 241-249.